Codagenix
NY · 4 filings, 2025
Lobbying spend · 2025
$110K
to shape legislation
About the organization
COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc. In December 2020, COVI-VAC started a Phase I clinical trial, involving 48 participants. via Wikipedia ↗
1Lobbies on
Its filings list: Budget/Appropriations
2Through these firms · 1
STRATEGIC MARKETING INNOVATIONS